Provided by Tiger Trade Technology Pte. Ltd.

Johnson & Johnson

270.83
+0.84000.31%
Volume:1.64M
Turnover:445.33M
Market Cap:652.51B
PE:31.36
High:273.73
Open:271.74
Low:268.59
Close:269.99
52wk High:281.07
52wk Low:173.33
Shares:2.41B
Float Shares:2.40B
Volume Ratio:0.35
T/O Rate:0.07%
Dividend:5.24
Dividend Rate:1.93%
EPS(TTM):8.64
EPS(LYR):11.03
ROE:25.74%
ROA:8.59%
PB:7.68
PE(LYR):24.55

Loading ...

J&J says Caplyta Phase 3 study in bipolar I met primary endpoint

TIPRANKS
·
Yesterday

Johnson & Johnson Says Phase 3 Trial Shows Caplyta Cuts Bipolar I Mania Symptoms by Week 3

Reuters
·
Yesterday

J&J - Caplyta Demonstrates Statistically Significant Rapid Reduction in Manic Symptoms at Week 3

THOMSON REUTERS
·
Yesterday

Caplyta® (Lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Pivotal Phase 3 Study

THOMSON REUTERS
·
Yesterday

J&J - Caplyta Well-Tolerated; Dry Mouth and Nausea Most Common Adverse Events

THOMSON REUTERS
·
Yesterday

LIVE Markets-Big Beauty Faces Growing Threat from AI, Smaller Rivals

Reuters
·
Yesterday

3 ‘Strong Buy’ Dividend Aristocrat Stocks to Generate Steady Cash

TIPRANKS
·
Sep 19

Estee Lauder Cos. Cl a Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 18

PepsiCo Adds Johnson & Johnson CEO Joaquin Duato to Board, Names Him to Audit Committee

Reuters
·
Sep 18

These ETFs Could Thrive in a Market Overcome by Interest-Rate Worries

Dow Jones
·
Sep 17

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 16

Estee Lauder Cos. Cl a Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 16

Health Rounds: New Dye for MRI Exams Detects Lung Cancer Earlier

Reuters
·
Sep 16

As Trump Backs Psychedelics Research, FDA Weighs Safety and Access Standards

Reuters
·
Sep 15

LIVE Markets-Autumn in New York: Factory Expansion Slows, Input Prices at Multi-Year Highs - Empire State

Reuters
·
Sep 15

LIVE Markets-US Stock Indexes Swing Lower as Oil, Yields Jump

Reuters
·
Sep 15

Dow's Nearly 300-Point Fall Led by Losses in Johnson & Johnson, Nike Stocks

Dow Jones
·
Sep 15

Johnson & Johnson Says Subcutaneous Cancer Treatment Study Shows Low Rates Across Key Events, Discontinuation

MT Newswires Live
·
Sep 15

JNJ Reports Low Rates of Treatment-Related Events for Rybrevant Faspro Plus Lazcluze at Wclc 2026

Reuters
·
Sep 15

J&J - Fewer than 1% Discontinue Rybrevant Faspro Plus Lazcluze Due to Treatment-Related Events at One Year

THOMSON REUTERS
·
Sep 15